CD8A and neoplasm: Alotinib is a new multi-target tyrosine kinase inhibitor [9] and has been shown in several preclinical studies to reverse resistance to immunotherapy by reshaping the immune microenvironment, including promoting tumor vascular normalization and inducing CD8+ T-cell infiltration into the tumor environment [10–12].